[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1997002010A1 - Bactericidal composition - Google Patents

Bactericidal composition Download PDF

Info

Publication number
WO1997002010A1
WO1997002010A1 PCT/US1996/009860 US9609860W WO9702010A1 WO 1997002010 A1 WO1997002010 A1 WO 1997002010A1 US 9609860 W US9609860 W US 9609860W WO 9702010 A1 WO9702010 A1 WO 9702010A1
Authority
WO
WIPO (PCT)
Prior art keywords
chelant
acid
bactericidal
mixtures
composition according
Prior art date
Application number
PCT/US1996/009860
Other languages
French (fr)
Inventor
Gerard Marcel Baillely
Robin Gibson Hall
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to CA002228945A priority Critical patent/CA2228945C/en
Priority to EP96919315A priority patent/EP0836469A4/en
Priority to AU61684/96A priority patent/AU6168496A/en
Publication of WO1997002010A1 publication Critical patent/WO1997002010A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005Antimicrobial preparations
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463Organic compounds; Microorganisms; Enzymes
    • A23L3/3481Organic compounds containing oxygen
    • A23L3/3508Organic compounds containing oxygen containing carboxyl groups
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L3/00Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
    • A23L3/34Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
    • A23L3/3454Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
    • A23L3/3463Organic compounds; Microorganisms; Enzymes
    • A23L3/3526Organic compounds containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/347Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/362Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41Amines
    • A61K8/416Quaternary ammonium compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/51Chelating agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00Anti-perspirants or body deodorants

Definitions

  • the present invention relates to the use of a chelant as a a bactericidal compound as well as a bactericidal composition containing a chelant, suitable for use in deodorants, soaps, oral health care, dermatological preparations and also in food as a food preservative. More particularly, it relates to a bactericidal composition comprising a chelant as a bactericidal agent or as a co-bactericidal agent.
  • Bacteria may be found in the food or clinic environment. Bacteria strains are divided into two types: gram negative and gram positive. Gram negative bacteria types include bacteria such as Salmonella typhimurium, Bacterioides gingivalis, Actinobacillus actinomycetescomitans, Klebsiella pneumoniae, Escherichia coli and Pseudomonas aeruginosa while gram positive bacteria include bacteria such as Staphilococcus aureus, Streptococcus mutans, Listeria monocytogenes, Streptococcus agalactiae and Coryneform bacteria.
  • Gram negative bacteria types include bacteria such as Salmonella typhimurium, Bacterioides gingivalis, Actinobacillus actinomycetescomitans, Klebsiella pneumoniae, Escherichia coli and Pseudomonas aeruginosa
  • gram positive bacteria include bacteria such as Staphilococcus aureus, Strept
  • bactericides of the bacterial or chemical type To retard and/or prevent such growth, it is known in the art to use bactericides of the bacterial or chemical type. However, a problem encountered with such bactericides is that they are expensive and/or sometimes are not fully active. Not to be bound by theory, it is believed that the cations present on the cell wall of the bacteria prevent the bactericidal action. The Applicant has found that the problems of bacteria growth and reduced bactericidal activity are particularly troublesome with bactericidal agents of the chlorophenol and/or quaternary ammonium type.
  • the formulator thus faces the challenge of formulating a product which maximises the bactericidal activity, minimises the contamination and is also inexpensive.
  • WO 89/1239 discloses the use of lanthionine containing bacteriocin and a chelating agent for inhibiting Gram negative bacteria growth. More particularly disclosed are lanthionine containing bacteriocins with ethylene diamine tetraacetic acid (EDTA) for inhibiting Pseudomonas aeruginosa growth.
  • EDTA ethylene diamine tetraacetic acid
  • EP 0,639,636 discloses the use of a cationic germicide with a chelating agent and a surfactant. More particularly disclosed are cationic germicides with EDTA and a surfactant for inhibiting gram negative bacteria growth such as Escherichia coli and Pseudomonas aeruginosa.
  • the present invention relates to the use of a chelant selected from the succinic acid, glutaric acid, phosphonic acid classes or any salts thereof and mixtures thereof as a bactericidal compound. Also provided herein are bactericidal compositions containing said chelant together with or without a conventional bactericidal agent.
  • a method for reducing the bacterial growth which comprises the step of exposing said bacteria strain with a bactericidal composition according to the invention.
  • An essential component of the invention is a chelant.
  • the chelant When used as a bactericidal compound per se, the chelant will be present in amount of at least 0.05%, preferably at least 0.7% and more preferably at least 1 % by weight of the composition.
  • said chelant When used as a co-bactericide, said chelant will be present in amount from at least 0.05%, preferably at least 0.5% and more preferably at least 1 % by weight of the composition.
  • Suitable chelants for the purpose of the invention are compounds selected from succinic acid, glutaric acid, phosphonic acid classes or any salts thereof and mixtures thereof.
  • Non limiting examples of chelants of the succinic acid class include emylenediamine disuccinic acid (EDDS), 2-hydroxypropy lenediamine disuccinic acid (HPDDS) and any salts thereof and mixtures thereof.
  • EDDS emylenediamine disuccinic acid
  • HPDDS 2-hydroxypropy lenediamine disuccinic acid
  • a suitable chelant of the glutaric acid class is ethylenediamine diglutaric acid (EDDG) or salt thereof.
  • Non limiting examples of chelants of the phosphonic acid class include emylenediaminetetrakis (methylenephosphonic acid), diethylene triamine penta (methylene phosphonic acid), ethylene diamine tri (methylene phosphonic acid), hexamethylene diamine tetra (methylene phosphonic acid), ⁇ -hydroxy-2 phenyl ethyl diphosphonic acid, methylene diphosphonic acid, hydroxy 1,1-hexylidene diphosphonic acid, vinylidene 1,1 diphosphonic acid, 1,2 dihydroxyethane 1,1 diphosphonic acid and hydroxy-ethane 1,1 diphosphonic acid and any salts thereof and mixtures thereof.
  • Preferred from the above phosphonic acid species is hydroxy-ethane 1,1 diphosphonic acid. More preferably, said chelants are selected from ethylenediamine disuccinic acid, ethylenediamine diglutaric acid, 2- hydroxypropylenediamine disuccinic acid, hydroxy ethane 1,1 diphosphonic acid or any salts thereof and mixtures thereof. Especially preferred is ethylenediarnine-N,N'-disuccinic acid or the alkali metal, alkaline earth metal, ammonium, or substituted ammomum salts thereof, or mixtures thereof.
  • Preferred EDDS compounds are the free acid form and the sodium or magnesium salt or complex thereof. Examples of such preferred sodium salts of EDDS include Na2EDDS and Na ⁇ EDDS. Examples of such preferred magnesium complexes of EDDS include MgEDDS and Mg2EDDS.
  • a bactericidal composition comprising a chelant, wherein said chelant is as defined herein before.
  • the bactericidal composition of the invention may further comprise one or more conventional bactericidal agents.
  • the combination of said conventional bactericidal agent with said chelant is seen to produce a synergistic action on bacteria strain, particularly on Gram negative bacteria types and more specifically on Pseudomonas aeruginosa.
  • the said combination allows the use of a reduced amount of conventional bactericides. More specifically, the combination produces a reduction in the minimum inhibitory concentration (MIC) of the conventional bactericide used per se.
  • MIC minimum inhibitory concentration
  • MIC is meant the “Minimum Inhibitory Concentration”, e.g the minimum level necessary of such conventional bactericides to inhibit the bacteria growth.
  • Conventional bactericidal agents of use herein, for the purpose of the invention, will be selected from agents having their original MIC (e.g when used without the presence of a chelant of the invention) reduced by at least 50%, preferably 70% and more preferably at least 90% when in the presence of said chelant.
  • bactericidal agents selected from chlorophenol and quaternary ammonium species and mixtures thereof.
  • chlorophenol species are compounds selected from 2,4,4' trichloro-2' -hydroxydiphenyl ether available under the tradename Irgasan DP 300 from Ciba Geigy, 2,2'-dihydroxy-5,5'-dibromo-diphenyl ether and mixtures thereof.
  • Preferred among the quaternary ammonium species is cetyl trimethyl ammonium bromide.
  • these conventional bactericides are selected from 2,4,4' trichloro-2 * -hydroxydiphenyl ether (Irgasan DP 300), cetyl trimethyl ammonium bromide and mixtures thereof.
  • a most preferred conventional bactericide to be used in combination with a chelant of the invention is 2,4,4' trichloro-2' -hydroxydiphenyl ether (Irgasan DP 300).
  • Additional compounds may also be added to the composition. Such additional compounds should not be detrimental to the bactericidal composition of the invention.
  • Non limiting examples of classes of suitable additional compounds which may be of use herein include surfactants, binders and thickeners.
  • Non limiting examples of surfactants useful herein typically at levels from 1% to 95%, preferably 1% to 55% by weight, include the conventional Cn-Ci8 alkyl benzene sulfonates ("LAS") and primary, branched-chain and random C10-C20 alkyl sulfates (“AS”), the C10-C18 secondary (2,3) alkyl sulfates of the formula CH3(CH2) (CHOS ⁇ 3 ⁇ M + ) CH3 and CH3 (CH2) y (CHOS ⁇ 3 " M ) CH2CH3 where x and y - 1) are integers of at least 7, preferably at least 9, and M is a water-solubilizing cation, especially sodium, unsaturated sulfates such as oleyl sulfate, the CiQ-Cis alkyl alkoxy sulfates ("AE S”; especially EO 1-7 ethoxy sulfates), C10-C18 alkyl alkoxy carboxylates (
  • the conventional nonionic and amphoteric surfactants such as the C ⁇ 2-C ⁇ g alkyl ethoxylates ("AE"), including the so-called narrow peaked alkyl ethoxylates and C6-C12 alkyl phenol alkoxylates (especially ethoxylates and mixed ethoxy/propoxy), C ⁇ 2-Cl8 betaines and sulfobetaines ("sultaines"), C10-C18 amine oxides, and the like, can also be included in the overall compositions.
  • the C10-C18 N-alkyl polyhydroxy fatty acid amides can also be used. Typical examples include the C12- 18 N- methylglucamides. See WO 9,206,154.
  • sugar-derived surfactants include the N-alkoxy polyhydroxy fatty acid amides, such as C10-C18 N (3-methoxypropyl) glucamide.
  • the N-propyl through N-hexyl C12-C18 glucamides can be used for low sudsing.
  • C10-C20 conventional soaps may also be used. If high sudsing is desired, the branched-chain C10- Ci6 soaps may be used.
  • Suitable surfactants suitable for the purpose of the invention are the anionic alkali metal sarcosinates of formula:
  • R is a C9-C17 linear or branched alkyl or alkenyl group
  • Rl is a C1-C4 alkyl group
  • M is an alkali metal ion.
  • Preferred examples are the lauroyl, cocoyl (C12-C14), myristyl and oleyl methyl sarcosinates in the form of their sodium salts.
  • Binders and thickeners such as sodium carboxymethylcellulose, xantham gum, gum arabic may also be included, as well as synthetic polymers such as polyacrylates, copolymers of polyvinylmethylether with maleic anhydride, copolymers of maleic acid with acrylic acid, terpolymers of maleic/acrylic/vinyl alcohol and hydroxy alkyl cellulose ethers.
  • Flavours such as peppermint and spearmint oils may also be included, as well as preservatives, opacifying agents, colouring agents, pH-adjusting agents and sweetening agents.
  • compositions of the invention can be formulated in any desirable form such as powders, granulates, pastes, liquids, tablets, capsules, pills, solutions, suspensions, salves and gels.
  • compositions of the present invention may be formulated as liquid compositions.
  • Such liquid compositions typically comprise from 94% to 35% by weight, preferably from 90% to 40% by weight, most preferably from 80% to 50% by weight of a liquid carrier, e.g., water, preferably a mixture of water and organic solvent.
  • compositions of the present invention may also be in the form of gels.
  • Such compositions are typically formulated with polyalkenyl polyether having a molecular weight of from about 750,000 to about 4,000,000.
  • compositions of the invention may also be in the form of solids, such as powders, tablets, capsules, pills and granules.
  • a method for reducing the growth of a bacteria strain which comprises the step of exposing said bacteria strain to a bactericidal composition of the invention.
  • a particularly effective action is seen on gram negative bacteria and more specifically Pseudomonas aeruginosa.
  • Cultures of the test bacterium were prepared with Pseudomonas aeruginosa in nutrient broth and subcultured at 30°C daily for between three and five successive days before they were required.
  • the inocula were prepared by diluting each of the overnight broth cultures 1:100 in
  • Solutions or suspensions of the antibacterials were prepared in sterile distilled water or water/ethanol mixtures immediately before use.
  • EDDS is seen to produce an effective bactericidal action against Pseudomonas aeruginosa bacteria.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

There is provided the use of a chelant selected from the succinic acid, glutaric acid, phosphonic acid classes or any salts thereof and mixture thereof as a bactericidal compound. Also provided herein are bactericidal compositions containing said chelant with or without conventional bactericidal agents. Further provided herein is a method for reducing the growth of a bacteria strain, which comprises the step of exposing said bacteria strain to a bactericidal composition of the invention.

Description

Bactericidal composition
Field of the invention
The present invention relates to the use of a chelant as a a bactericidal compound as well as a bactericidal composition containing a chelant, suitable for use in deodorants, soaps, oral health care, dermatological preparations and also in food as a food preservative. More particularly, it relates to a bactericidal composition comprising a chelant as a bactericidal agent or as a co-bactericidal agent.
Background of the invention
Bacteria may be found in the food or clinic environment. Bacteria strains are divided into two types: gram negative and gram positive. Gram negative bacteria types include bacteria such as Salmonella typhimurium, Bacterioides gingivalis, Actinobacillus actinomycetescomitans, Klebsiella pneumoniae, Escherichia coli and Pseudomonas aeruginosa while gram positive bacteria include bacteria such as Staphilococcus aureus, Streptococcus mutans, Listeria monocytogenes, Streptococcus agalactiae and Coryneform bacteria.
The presence of such bacteria on food or dermatological or oral substrates results in contamination and spoilage. This problem is magnified for gram negative bacteria, especially Pseudomonas aeruginosa as this microoganism is distributed widely and also spreads rapidly since almost any condition is suitable for its growth.
To retard and/or prevent such growth, it is known in the art to use bactericides of the bacterial or chemical type. However, a problem encountered with such bactericides is that they are expensive and/or sometimes are not fully active. Not to be bound by theory, it is believed that the cations present on the cell wall of the bacteria prevent the bactericidal action. The Applicant has found that the problems of bacteria growth and reduced bactericidal activity are particularly troublesome with bactericidal agents of the chlorophenol and/or quaternary ammonium type.
The formulator thus faces the challenge of formulating a product which maximises the bactericidal activity, minimises the contamination and is also inexpensive.
WO 89/1239 discloses the use of lanthionine containing bacteriocin and a chelating agent for inhibiting Gram negative bacteria growth. More particularly disclosed are lanthionine containing bacteriocins with ethylene diamine tetraacetic acid (EDTA) for inhibiting Pseudomonas aeruginosa growth.
EP 0,639,636 discloses the use of a cationic germicide with a chelating agent and a surfactant. More particularly disclosed are cationic germicides with EDTA and a surfactant for inhibiting gram negative bacteria growth such as Escherichia coli and Pseudomonas aeruginosa.
The Applicant has now surprisingly found that the use of specific chelants of the succinic, glutaric or phosphonic class ameliorate these problems.
It is therefore an object of the invention to provide the use of a compound having a bactericidal activity.
It is another object of the invention to provide bactericidal compositions containing a chelant.
It is a further object of the invention to provide bactericidal compositions containing a chelant together with a conventional bactericidal compound, wherein the combination of said chelant with the conventional bactericidal compound produce a synergistic bactericidal action.
Summary of the invention
The present invention relates to the use of a chelant selected from the succinic acid, glutaric acid, phosphonic acid classes or any salts thereof and mixtures thereof as a bactericidal compound. Also provided herein are bactericidal compositions containing said chelant together with or without a conventional bactericidal agent.
Further provided herein is a method for reducing the bacterial growth, which comprises the step of exposing said bacteria strain with a bactericidal composition according to the invention.
Detailed description of the invention Chelant
An essential component of the invention is a chelant. When used as a bactericidal compound per se, the chelant will be present in amount of at least 0.05%, preferably at least 0.7% and more preferably at least 1 % by weight of the composition. When used as a co-bactericide, said chelant will be present in amount from at least 0.05%, preferably at least 0.5% and more preferably at least 1 % by weight of the composition.
Suitable chelants for the purpose of the invention are compounds selected from succinic acid, glutaric acid, phosphonic acid classes or any salts thereof and mixtures thereof.
Non limiting examples of chelants of the succinic acid class include emylenediamine disuccinic acid (EDDS), 2-hydroxypropy lenediamine disuccinic acid (HPDDS) and any salts thereof and mixtures thereof.
A suitable chelant of the glutaric acid class is ethylenediamine diglutaric acid (EDDG) or salt thereof.
Non limiting examples of chelants of the phosphonic acid class include emylenediaminetetrakis (methylenephosphonic acid), diethylene triamine penta (methylene phosphonic acid), ethylene diamine tri (methylene phosphonic acid), hexamethylene diamine tetra (methylene phosphonic acid), α-hydroxy-2 phenyl ethyl diphosphonic acid, methylene diphosphonic acid, hydroxy 1,1-hexylidene diphosphonic acid, vinylidene 1,1 diphosphonic acid, 1,2 dihydroxyethane 1,1 diphosphonic acid and hydroxy-ethane 1,1 diphosphonic acid and any salts thereof and mixtures thereof.
Preferred from the above phosphonic acid species is hydroxy-ethane 1,1 diphosphonic acid. More preferably, said chelants are selected from ethylenediamine disuccinic acid, ethylenediamine diglutaric acid, 2- hydroxypropylenediamine disuccinic acid, hydroxy ethane 1,1 diphosphonic acid or any salts thereof and mixtures thereof. Especially preferred is ethylenediarnine-N,N'-disuccinic acid or the alkali metal, alkaline earth metal, ammonium, or substituted ammomum salts thereof, or mixtures thereof. Preferred EDDS compounds are the free acid form and the sodium or magnesium salt or complex thereof. Examples of such preferred sodium salts of EDDS include Na2EDDS and NaβEDDS. Examples of such preferred magnesium complexes of EDDS include MgEDDS and Mg2EDDS.
In an embodiment of the invention is provided a bactericidal composition comprising a chelant, wherein said chelant is as defined herein before.
In another embodiment of the invention, the bactericidal composition of the invention may further comprise one or more conventional bactericidal agents. The combination of said conventional bactericidal agent with said chelant is seen to produce a synergistic action on bacteria strain, particularly on Gram negative bacteria types and more specifically on Pseudomonas aeruginosa.
Furthermore, the said combination allows the use of a reduced amount of conventional bactericides. More specifically, the combination produces a reduction in the minimum inhibitory concentration (MIC) of the conventional bactericide used per se.
By MIC is meant the "Minimum Inhibitory Concentration", e.g the minimum level necessary of such conventional bactericides to inhibit the bacteria growth.
Determination of said MIC is described hereinafter.
Conventional bactericidal agents
Conventional bactericidal agents of use herein, for the purpose of the invention, will be selected from agents having their original MIC (e.g when used without the presence of a chelant of the invention) reduced by at least 50%, preferably 70% and more preferably at least 90% when in the presence of said chelant.
Most preferred conventional bactericidal agents which may be used for the purpose of the invention are bactericidal agents selected from chlorophenol and quaternary ammonium species and mixtures thereof. Preferred among the chlorophenol species are compounds selected from 2,4,4' trichloro-2' -hydroxydiphenyl ether available under the tradename Irgasan DP 300 from Ciba Geigy, 2,2'-dihydroxy-5,5'-dibromo-diphenyl ether and mixtures thereof.
Preferred among the quaternary ammonium species is cetyl trimethyl ammonium bromide.
More preferably, these conventional bactericides are selected from 2,4,4' trichloro-2* -hydroxydiphenyl ether (Irgasan DP 300), cetyl trimethyl ammonium bromide and mixtures thereof. A most preferred conventional bactericide to be used in combination with a chelant of the invention is 2,4,4' trichloro-2' -hydroxydiphenyl ether (Irgasan DP 300).
Additional compounds may also be added to the composition. Such additional compounds should not be detrimental to the bactericidal composition of the invention.
Non limiting examples of classes of suitable additional compounds which may be of use herein include surfactants, binders and thickeners.
Surfactant
Non limiting examples of surfactants useful herein, typically at levels from 1% to 95%, preferably 1% to 55% by weight, include the conventional Cn-Ci8 alkyl benzene sulfonates ("LAS") and primary, branched-chain and random C10-C20 alkyl sulfates ("AS"), the C10-C18 secondary (2,3) alkyl sulfates of the formula CH3(CH2) (CHOSθ3~M+) CH3 and CH3 (CH2)y(CHOSθ3"M ) CH2CH3 where x and y - 1) are integers of at least 7, preferably at least 9, and M is a water-solubilizing cation, especially sodium, unsaturated sulfates such as oleyl sulfate, the CiQ-Cis alkyl alkoxy sulfates ("AE S"; especially EO 1-7 ethoxy sulfates), C10-C18 alkyl alkoxy carboxylates (especially the EO 1-5 ethoxycarboxylates), the Cιo_i8 glycerol ethers, the Cio-Cig alkyl polyglycosides and their corresponding sulfated polyglycosides, and C12-C18 alpha-sulfonated fatty acid esters. If desired, the conventional nonionic and amphoteric surfactants such as the Cχ2-Cιg alkyl ethoxylates ("AE"), including the so-called narrow peaked alkyl ethoxylates and C6-C12 alkyl phenol alkoxylates (especially ethoxylates and mixed ethoxy/propoxy), Cχ2-Cl8 betaines and sulfobetaines ("sultaines"), C10-C18 amine oxides, and the like, can also be included in the overall compositions. The C10-C18 N-alkyl polyhydroxy fatty acid amides can also be used. Typical examples include the C12- 18 N- methylglucamides. See WO 9,206,154. Other sugar-derived surfactants include the N-alkoxy polyhydroxy fatty acid amides, such as C10-C18 N (3-methoxypropyl) glucamide. The N-propyl through N-hexyl C12-C18 glucamides can be used for low sudsing. C10-C20 conventional soaps may also be used. If high sudsing is desired, the branched-chain C10- Ci6 soaps may be used.
Other suitable surfactants suitable for the purpose of the invention are the anionic alkali metal sarcosinates of formula:
Figure imgf000008_0001
wherein R is a C9-C17 linear or branched alkyl or alkenyl group, Rl is a C1-C4 alkyl group and M is an alkali metal ion. Preferred examples are the lauroyl, cocoyl (C12-C14), myristyl and oleyl methyl sarcosinates in the form of their sodium salts.
Mixtures of anionic and nonionic surfactants are especially useful. Other conventional useful surfactants are listed in standard texts.
Binders and thickeners such as sodium carboxymethylcellulose, xantham gum, gum arabic may also be included, as well as synthetic polymers such as polyacrylates, copolymers of polyvinylmethylether with maleic anhydride, copolymers of maleic acid with acrylic acid, terpolymers of maleic/acrylic/vinyl alcohol and hydroxy alkyl cellulose ethers. Flavours such as peppermint and spearmint oils may also be included, as well as preservatives, opacifying agents, colouring agents, pH-adjusting agents and sweetening agents.
Form of the compositions The compositions of the invention can be formulated in any desirable form such as powders, granulates, pastes, liquids, tablets, capsules, pills, solutions, suspensions, salves and gels.
Liquid compositions
The compositions of the present invention may be formulated as liquid compositions. Such liquid compositions typically comprise from 94% to 35% by weight, preferably from 90% to 40% by weight, most preferably from 80% to 50% by weight of a liquid carrier, e.g., water, preferably a mixture of water and organic solvent.
Gel compositions
The compositions of the present invention may also be in the form of gels. Such compositions are typically formulated with polyalkenyl polyether having a molecular weight of from about 750,000 to about 4,000,000.
Solid compositions
The compositions of the invention may also be in the form of solids, such as powders, tablets, capsules, pills and granules.
In another embodiment of the invention there is provided a method for reducing the growth of a bacteria strain, which comprises the step of exposing said bacteria strain to a bactericidal composition of the invention.
A particularly effective action is seen on gram negative bacteria and more specifically Pseudomonas aeruginosa.
The invention is illustrated in the following non limiting examples.
Method of determination of the bactericidal activity
1 -Preparation of the inoculum
Cultures of the test bacterium were prepared with Pseudomonas aeruginosa in nutrient broth and subcultured at 30°C daily for between three and five successive days before they were required. The inocula were prepared by diluting each of the overnight broth cultures 1:100 in
0.1% Peptone Water immediately prior to use. /02010 P 17US96 09860
8
2-Determination of the Minimum Inhibitory Concentration (MIC) of
EDDS
5ml of the solution of 32.4% trisodium EDDS were added to 5ml of double strength nutrient broth and mixed. 5 ml of this mixture were taken and added to 5ml of single strength broth and mixed. Further halving dilutions were prepared in the same manner until a total of ten dilutions of the product had been prepared.
3-Preparation of solutions of antibacterials
Solutions or suspensions of the antibacterials were prepared in sterile distilled water or water/ethanol mixtures immediately before use.
4-Preparation of nutrient broth containing EDDS Single strength (0.745%) solutions of EDDS in nutrient broth were prepared by adding 2.3ml of 32.4% trisodium EDDS to 97.7ml single strength nutrient broth. Double strength (1.49%) solutions of EDDS in double strength nutrient broth were prepared by adding 4.6ml of 32.4% trisodium EDDS to 95.4ml double strength nutrient broth.
5-Preparation of dilutions of the antibacterials
5ml of the solution or suspension of antibacterial were added to 5ml of double strength nutrient broth and mixed; 5ml of this mixture were taken and added to 5ml of single strength broth and mixed. Further halving dilutions were prepared in the same manner until a total of ten dilutions of the product had been prepared. This operation was repeated but this time all dilutions were prepared in nutrient broth containing EDDS prepared as in point 4.
6-Determination of the MIC of the conventional bactericidal agents Halving dilutions in nutrient broth of each antibacterial prepared in triplicate as in point 5 were inoculated with 10 microlitres of the inoculum and mixed. The inoculated broths were incubated at 30°C for 3 days and then examined for visual turbidity. The presence of turbidity, noted " + " in the examples, was taken as an indicator of bacterial growth and multiplication. 02010
Example 1
MIC of trisodium salt of EDDS (Concentration in dilution Nol = 16.2%)
1 2 3 4 5 6 7 8 9 10
- - - - - + + + + +
- - - - - + + + + +
- - - - - + + + + +
MIC = 0.506-1.013%
At levels of at least 0.7%, EDDS is seen to produce an effective bactericidal action against Pseudomonas aeruginosa bacteria.
Example 2
MIC of Cetyl trimethyl ammonium bromide (ex BDH) (Concentration in dilution Nol =0.5%)
1 2 3 4 5 6 7 8 9 10
- - - - + + + + + +
- - - - + + + + + +
- - - - + + + + + +
MIC = 0.0313-0.0625%
MIC of Cetyl trimethyl ammonium bromide in broth containing 0.745% EDDS (Concentration in dilution Nol =0.5%)
1 2 3 4 5 6 7 8 9 10
- - - - - - - - - +
- - - - - - - - - -
- - - - - - - - - +
MIC = 0.000977-0.00195%
It can be seen that the combination of EDDS and cetyl trimethyl ammonium bromide produce a synergistic bactericidal action. Example 3
MIC of 2,4,4' trichloro-2*-hydroxydiphenyl ether (Irgasan DP 300 ex
Ciba-Geigy) (Concentration in dilution Nol =0.5%)
1 2 3 4 5 6 7 8 9 10
- + + + + + + + + +
- + + + + + + + + +
- + + + + + + + + +
MIC = > 0.5%-inhibition in dilution Nol due to presence of ethanol
MIC of 2,4,4' trichloro-2'-hydroxydiphenyl ether (Irgasan DP 300) in broth containing 0.745% EDDS (Concentration in dilution Nol =0.5%)
1 2 3 4 5 6 7 8 9 10
- - - - - - + + + +
- - - - - - + + + +
- - - - - - - + + +
MIC = 0.00781-0.0156%
It can be seen that the combination of EDDS and 2,4,4' trichloro-2'- hydroxydiphenyl ether (Irgasan DP 300) produce a synergistic bactericidal action.

Claims

WHAT IS CLAIMED IS:
1-The use of a chelant selected from the succinic acid, glutaric acid, phosphonic acid classes or any salts thereof and mixtures thereof as a bactericidal compound.
2-The use of a chelant according to Claim 1, wherein said chelant is selected from emylenediamine disuccinic acid (EDDS), ethylenediamine diglutaric acid (EDDG), 2-hydroxypropylenediamine disuccinic acid (HPDDS), hydroxy ethane 1,1 diphosphonic acid (HEDP) or any salts thereof and mixtures thereof.
3-The use of a chelant according to either one of Claim 1 or 2, wherein said chelant is ethylenediamine disuccinic acid (EDDS) or salt thereof.
4-A bactericidal composition, wherein said composition comprises a chelant selected from the succinic acid, glutaric acid, phosphonic acid classes or any salts thereof and mixtures thereof.
5-A bactericidal composition according to Claim 4, wherein said chelant is selected from ethylenediamine disuccinic acid (EDDS), e ylenediamine diglutaric acid (EDDG), 2-hydroxypropylenediamine disuccinic acid (HPDDS), hydroxy ethane 1,1 diphosphonic acid (HEDP) or any salts thereof and mixtures thereof.
6-A bactericidal composition according to either one of Claim 4 or 5, wherein said chelant is ethylenediamine disuccinic acid (EDDS) or salt thereof.
7-A bactericidal composition according to any one of Claim 4-6, wherein said chelant is present in amount of at least 0.05%, preferably 0.7% by weight.
8-A bactericidal composition according to any one of Claims 4-6, wherein said composition further comprises a conventional bactericidal agent. 7/02010 PC17US96/09860
12
9- A composition according to Claim 8, wherein said chelant is present in amount of at least 0.05%, preferably at least 0.5% by weight.
10-A composition according to either one of Claim 8 or 9, wherein said conventional bactericide is selected from agents having their original Minimum Inhibitory Concentration (MIC) reduced by at least 50%, preferably 70% and more preferably at least 90% when in the presence of said chelant.
11-A composition according to anyone of Claims 8-10, wherein said conventional bactericide is selected from chlorophenol and quaternary ammonium species and mixtures thereof.
12-A composition according to Claim 11, wherein said conventional bactericide is selected from 2,4,4' trichloro-2' -hydroxydiphenyl ether (Irgasan DP 300), cetyl trimethyl ammonium bromide and mixtures thereof, preferably 2,4,4' trichloro-2' -hydroxydiphenyl ether (Irgasan DP 300).
13-A method for reducing the growth of a bacteria strain, which comprises the step of exposing said bacteria strain to a bactericidal composition as claimed in any one of Claims 4-12.
14-A method according to Claim 11, wherein said bacteria strain is of the gram negative type and preferably is Pseudomonas aeruginosa.
PCT/US1996/009860 1995-07-05 1996-06-07 Bactericidal composition WO1997002010A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002228945A CA2228945C (en) 1995-07-05 1996-06-07 Bactericidal composition
EP96919315A EP0836469A4 (en) 1995-07-05 1996-06-07 Bactericidal composition
AU61684/96A AU6168496A (en) 1995-07-05 1996-06-07 Bactericidal composition

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9513731.1A GB9513731D0 (en) 1995-07-05 1995-07-05 Bactericidal compositions
GB9513731.1 1995-07-05

Publications (1)

Publication Number Publication Date
WO1997002010A1 true WO1997002010A1 (en) 1997-01-23

Family

ID=10777188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/009860 WO1997002010A1 (en) 1995-07-05 1996-06-07 Bactericidal composition

Country Status (5)

Country Link
EP (1) EP0836469A4 (en)
AU (1) AU6168496A (en)
CA (1) CA2228945C (en)
GB (1) GB9513731D0 (en)
WO (1) WO1997002010A1 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004237A1 (en) * 1996-07-25 1998-02-05 The Procter & Gamble Company Shampoo compositions
WO1998024400A2 (en) * 1996-12-03 1998-06-11 Basf Aktiengesellschaft Use of bis(dicarboxylic acid) diaminoalkylene derivatives as biologically degradable complexing agents for alkaline earth metal ions and heavy metal ions
WO1999018791A1 (en) * 1997-10-09 1999-04-22 The Associated Octel Company Limited Anti-microbial compound
EP0968658A1 (en) * 1998-07-02 2000-01-05 Akzo Nobel N.V. Feed additives comprising ethylene diamine disuccinic acid as a chelant
WO2002047484A1 (en) * 2000-12-15 2002-06-20 Laboratoires Anios Composition for treating objects to be disinfected
US6503490B2 (en) 2000-10-09 2003-01-07 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Deodorant products
JP2004002289A (en) * 2002-03-25 2004-01-08 Shiseido Co Ltd Parakeratosis inhibitor
WO2010078069A1 (en) * 2008-12-30 2010-07-08 Pepsico, Inc. Preservative system for acidic beverages based on sequestrants
EP2206506A1 (en) 2008-12-18 2010-07-14 Bracco Imaging S.p.A Probiotic formulations
WO2010121884A1 (en) * 2009-04-20 2010-10-28 Unilever Plc Stabilized cationic ammonium compounds and compositions comprising the same
US8324255B2 (en) 2009-09-15 2012-12-04 Conopco, Inc. Chelator stabilized cationic ammonium compounds and compositions comprising the same
US8377478B2 (en) 2007-07-26 2013-02-19 Innospec Limited Solid detergent composition
US8628683B2 (en) 2007-07-26 2014-01-14 Innospec Limited Adduct of 1-hydroxyethylidene-1, 1-diphosphonic acid and ethylenediamine disuccinic acid or a salt thereof, a method for its preparation, and the use of said adduct
WO2018206449A1 (en) * 2017-05-10 2018-11-15 Henkel Ag & Co. Kgaa Methods for reducing sweat and/or body odor, using phosphonate compounds with amine and/or hydroxyl groups

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4541944A (en) * 1983-04-14 1985-09-17 Interox Chemicals Limited Compositions and processes employing activators for the generation of peroxyacids
US4719050A (en) * 1986-04-05 1988-01-12 Henkel Kommanditgesellschaft Auf Aktien Diphosponylated oxonitriles, processes and uses therefor, and compositions containing them
US5407949A (en) * 1985-01-18 1995-04-18 Cetylite Industries, Inc. Sterilant composition
US5460802A (en) * 1994-07-18 1995-10-24 Minnesota Mining And Manufacturing Company Oral disinfectant for companion animals
US5462692A (en) * 1990-11-30 1995-10-31 Peroxid-Chemie Gmbh Stable solid acetylperoxyborate compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892724A (en) * 1988-05-09 1990-01-09 The B. F. Goodrich Company Tartar inhibiting oral compositions and method
WO1994000103A1 (en) * 1992-06-26 1994-01-06 The Procter & Gamble Company Anticalculus compositions
EP0719089B1 (en) * 1993-09-14 1998-09-30 Minnesota Mining And Manufacturing Company Disinfectant composition

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4541944A (en) * 1983-04-14 1985-09-17 Interox Chemicals Limited Compositions and processes employing activators for the generation of peroxyacids
US5407949A (en) * 1985-01-18 1995-04-18 Cetylite Industries, Inc. Sterilant composition
US4719050A (en) * 1986-04-05 1988-01-12 Henkel Kommanditgesellschaft Auf Aktien Diphosponylated oxonitriles, processes and uses therefor, and compositions containing them
US5462692A (en) * 1990-11-30 1995-10-31 Peroxid-Chemie Gmbh Stable solid acetylperoxyborate compounds
US5460802A (en) * 1994-07-18 1995-10-24 Minnesota Mining And Manufacturing Company Oral disinfectant for companion animals

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0836469A4 *

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004237A1 (en) * 1996-07-25 1998-02-05 The Procter & Gamble Company Shampoo compositions
WO1998024400A2 (en) * 1996-12-03 1998-06-11 Basf Aktiengesellschaft Use of bis(dicarboxylic acid) diaminoalkylene derivatives as biologically degradable complexing agents for alkaline earth metal ions and heavy metal ions
WO1998024400A3 (en) * 1996-12-03 1998-07-16 Basf Ag Use of bis(dicarboxylic acid) diaminoalkylene derivatives as biologically degradable complexing agents for alkaline earth metal ions and heavy metal ions
WO1999018791A1 (en) * 1997-10-09 1999-04-22 The Associated Octel Company Limited Anti-microbial compound
EP0968658A1 (en) * 1998-07-02 2000-01-05 Akzo Nobel N.V. Feed additives comprising ethylene diamine disuccinic acid as a chelant
US6503490B2 (en) 2000-10-09 2003-01-07 Unilever Home & Personal Care Usa, Division Of Conopco, Inc. Deodorant products
WO2002047484A1 (en) * 2000-12-15 2002-06-20 Laboratoires Anios Composition for treating objects to be disinfected
FR2818150A1 (en) * 2000-12-15 2002-06-21 Anios Lab Sarl COMPOSITION FOR THE TREATMENT OF OBJECTS FOR DISINFECTION
JP2004002289A (en) * 2002-03-25 2004-01-08 Shiseido Co Ltd Parakeratosis inhibitor
US8377478B2 (en) 2007-07-26 2013-02-19 Innospec Limited Solid detergent composition
US8759397B2 (en) 2007-07-26 2014-06-24 Innospec Limited Detergent composition
US8628683B2 (en) 2007-07-26 2014-01-14 Innospec Limited Adduct of 1-hydroxyethylidene-1, 1-diphosphonic acid and ethylenediamine disuccinic acid or a salt thereof, a method for its preparation, and the use of said adduct
JP2012512828A (en) * 2008-12-18 2012-06-07 ブラッコ・イメージング・ソシエタ・ペル・アチオニ Probiotic formulation
EP2206506A1 (en) 2008-12-18 2010-07-14 Bracco Imaging S.p.A Probiotic formulations
US10631557B2 (en) 2008-12-30 2020-04-28 Pepsico, Inc. Preservative system for acidic beverages based on sequestrants
US9560871B2 (en) 2008-12-30 2017-02-07 Pepsico, Inc. Preservative system for acidic beverages based on sequestrants
WO2010078069A1 (en) * 2008-12-30 2010-07-08 Pepsico, Inc. Preservative system for acidic beverages based on sequestrants
US8628812B2 (en) 2008-12-30 2014-01-14 Pepsico, Inc. Preservative system for acidic beverages based on sequestrants
US8257720B2 (en) 2009-04-20 2012-09-04 Conopco, Inc. Stabilized cationic ammonium compounds and compositions comprising the same
WO2010121884A1 (en) * 2009-04-20 2010-10-28 Unilever Plc Stabilized cationic ammonium compounds and compositions comprising the same
US8765793B2 (en) 2009-09-15 2014-07-01 Conopco, Inc. Compositions with skin benefit compounds and chelator stabilized cationic ammonium compounds
US8324255B2 (en) 2009-09-15 2012-12-04 Conopco, Inc. Chelator stabilized cationic ammonium compounds and compositions comprising the same
WO2018206449A1 (en) * 2017-05-10 2018-11-15 Henkel Ag & Co. Kgaa Methods for reducing sweat and/or body odor, using phosphonate compounds with amine and/or hydroxyl groups

Also Published As

Publication number Publication date
GB9513731D0 (en) 1995-09-06
AU6168496A (en) 1997-02-05
EP0836469A1 (en) 1998-04-22
EP0836469A4 (en) 1999-09-15
CA2228945C (en) 2001-05-01
CA2228945A1 (en) 1997-01-23

Similar Documents

Publication Publication Date Title
CA2228945C (en) Bactericidal composition
BE1001110A5 (en) Composition use oral including polyphosphate and antibacterial agent and method of use for inhibiting scale plate and dental.
JP2019123889A (en) Liquid composition for cleaning and disinfection
CA2952669C (en) Oral care compositions comprising zinc, arginine and serine
AU2014403865B2 (en) Mouthwash composition comprising a peroxide source and an N alpha-acyl-L-arginine alkyl ester salt
BE1001658A5 (en) TOOTHPASTE COMPOSITION Antiplaque STABLE.
JPS60146817A (en) Sanitary agent for mouth and thooth
FR2599623A1 (en) ANTI-PLATE COMPOSITION FOR MOUTH USE BASED ON HEXETIDINE AND TRIDECANOL
JP2008156288A (en) Composition for oral cavity
DE102006029344A1 (en) Dental treatment agent with enhanced bleaching effect
US10624828B2 (en) Personal care compositions comprising a 2-pyridinol N-oxide material and an iron chelator
CN105792809B (en) Oral composition
TWI496589B (en) Oral care compositions and uses thereof in oral cavity and skin
JP2011105635A (en) Oral cavity composition
WO1992018091A1 (en) Antimicrobial oral compositions
US4886658A (en) Oral treatment method for reducing plaque with reduced staining
WO2020104216A1 (en) An antimicrobial composition for selectively inhibiting growth of p. acnes bacteria
US3989827A (en) Antibacterial composition
CA1083482A (en) Eye make-up remover
US2380011A (en) Germicidal preparations
FR2828808A1 (en) COMPOSITION
CA2482230A1 (en) Polyphosphonate derivatives for toothpaste compositions
JP2005187377A (en) Oral cavity biofilm inhibitory composition
JP2008174542A (en) Oral composition
WO1995008920A1 (en) Substantive antimicrobial phosphates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996919315

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2228945

Country of ref document: CA

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1996919315

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996919315

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)